Serono launches new injector device

Swiss biotech company Serono has launched the Rebiject II auto-injector, a device specifically designed to make self-injection of Rebif (interferon beta-1a) more convenient for multiple sclerosis (MS) patients.

Rebiject II is specifically designed for use with the Rebif pre-filled syringe. It provides several advantages over the previous auto-injector:

•Fewer steps are needed to inject - no need to remove the plunger from the pre-filled syringe;

•An adjustable needle depth regulator to allow the injector be tailored to each patient;

•A visual signal to show patients that the injection has been fully delivered;

•A safety mechanism to minimise the chance of accidental activation that could result in loss of medication;

•Better design making it easier for MS patients to handle, with a square, non-rolling, non-slip rubber grip.

A study conducted in 115 patients with MS on Rebif therapy showed that 71% found the new Rebiject II was better than their previous injection method. Patient feedback indicated that injections were less painful, and that the Rebiject II was easier to use than the previous Rebiject mini auto-injector or manual injection.

'Rebiject II should make Rebif administration easier and help to support treatment compliance for multiple sclerosis patients,' said Franck Latrille, head of product development at Serono.

The new Rebiject II auto-injector is expected to be available worldwide by the end of 2004.